Eli Lilly Financials
| LLY Stock | MXN 15,422 5.88 0.04% |
Eli |
Please note, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Check Eli Lilly's Beneish M Score to see the likelihood of Eli Lilly's management manipulating its earnings.
Eli Lilly Stock Summary
Eli Lilly competes with Merck, Roche Holding, Bristol Myers, and Amgen. Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people.| Foreign Associates | |
| Instrument | Mexico Stock View All |
| Exchange | Mexican Exchange |
| Business Address | Lilly Corporate Center, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.lilly.com |
| Phone | 317 276 2000 |
| Currency | MXN - Mexican Peso |
You should never invest in Eli Lilly without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Eli Stock, because this is throwing your money away. Analyzing the key information contained in Eli Lilly's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Eli Lilly Key Financial Ratios
Eli Lilly's financial ratios allow both analysts and investors to convert raw data from Eli Lilly's financial statements into concise, actionable information that can be used to evaluate the performance of Eli Lilly over time and compare it to other companies across industries.Eli Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eli Lilly's current stock value. Our valuation model uses many indicators to compare Eli Lilly value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eli Lilly competition to find correlations between indicators driving Eli Lilly's intrinsic value. More Info.Eli Lilly and is rated third overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers reporting about 0.18 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eli Lilly and is roughly 5.63 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eli Lilly by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eli Lilly's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Eli Lilly Systematic Risk
Eli Lilly's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eli Lilly volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Eli Lilly correlated with the market. If Beta is less than 0 Eli Lilly generally moves in the opposite direction as compared to the market. If Eli Lilly Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eli Lilly is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eli Lilly is generally in the same direction as the market. If Beta > 1 Eli Lilly moves generally in the same direction as, but more than the movement of the benchmark.
Eli Lilly December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eli Lilly help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eli Lilly and. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eli Lilly and based on widely used predictive technical indicators. In general, we focus on analyzing Eli Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eli Lilly's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 12.41 | |||
| Value At Risk | (4.46) | |||
| Potential Upside | 3.05 |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.